Anti-ABL monoclonal antibody

Pre-made anti-ABL monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ABL/ABL1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T63505-Ab-1/ GM-Tg-hg-T63505-Ab-2Anti-Human ABL/ABL1 monoclonal antibodyHuman
GM-Tg-rg-T63505-Ab-1/ GM-Tg-rg-T63505-Ab-2Anti-Rat ABL/ABL1 monoclonal antibodyRat
GM-Tg-mg-T63505-Ab-1/ GM-Tg-mg-T63505-Ab-2Anti-Mouse ABL/ABL1 monoclonal antibodyMouse
GM-Tg-cynog-T63505-Ab-1/ GM-Tg-cynog-T63505-Ab-2Anti-Cynomolgus/ Rhesus macaque ABL/ABL1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T63505-Ab-1/ GM-Tg-felg-T63505-Ab-2Anti-Feline ABL/ABL1 monoclonal antibodyFeline
GM-Tg-cang-T63505-Ab-1/ GM-Tg-cang-T63505-Ab-2Anti-Canine ABL/ABL1 monoclonal antibodyCanine
GM-Tg-bovg-T63505-Ab-1/ GM-Tg-bovg-T63505-Ab-2Anti-Bovine ABL/ABL1 monoclonal antibodyBovine
GM-Tg-equg-T63505-Ab-1/ GM-Tg-equg-T63505-Ab-2Anti-Equine ABL/ABL1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T63505-Ab-1/ GM-Tg-hg-T63505-Ab-2; GM-Tg-rg-T63505-Ab-1/ GM-Tg-rg-T63505-Ab-2;
GM-Tg-mg-T63505-Ab-1/ GM-Tg-mg-T63505-Ab-2; GM-Tg-cynog-T63505-Ab-1/ GM-Tg-cynog-T63505-Ab-2;
GM-Tg-felg-T63505-Ab-1/ GM-Tg-felg-T63505-Ab-2; GM-Tg-cang-T63505-Ab-1/ GM-Tg-cang-T63505-Ab-2;
GM-Tg-bovg-T63505-Ab-1/ GM-Tg-bovg-T63505-Ab-2; GM-Tg-equg-T63505-Ab-1/ GM-Tg-equg-T63505-Ab-2
Products NameAnti-ABL/ABL1 monoclonal antibody
Formatmab
Target NameABL
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-ABL monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T63505-Ag-1Recombinant multi-species ABL1/ ABL/ CHDSKM protein


    Target information

    Target IDGM-T63505
    Target NameABL
    Gene ID25,11350,311860,722449,491292,101087622,540876,100069715
    Gene Symbol and SynonymsABL,ABL1,BCR-ABL,bcr/abl,c-ABL,c-ABL1,CHDSKM,E430008G22Rik,JTK7,p150,v-abl
    Uniprot AccessionP00519
    Uniprot Entry NameABL1_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseCancer
    Gene EnsemblENSG00000097007
    Target ClassificationKinase, Tumor-associated antigen (TAA)

    The target: ABL, gene name: ABL1, also named as ABL, CHDSKM, JTK7, bcr/abl, c-ABL, c-ABL1, p150, v-abl. This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.